Latest Hotspot

Sosei Heptares Regains Full Rights to Oral GPR35 Activator HTL0027477 from GSK for Inflammatory Bowel Trials

26 March 2024
3 min read

Sosei Group Corporation has declared that it has reacquired complete control over HTL0027477 (formerly GSK4381406), a development-stage, orally administered GPR35 agonist with high selectivity and novel properties, intended as an innovative therapy option for Inflammatory Bowel Diseases. This compound is poised to enter clinical trials.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

GPR35 stands out as a key orphan receptor within the G protein-coupled receptor (GPCR) family, closely linked to inflammatory bowel disease (IBD), a condition that still presents a substantial care gap affecting millions globally.

Conceived by Sosei Heptares through its unique structure-based drug design technology, HTL0027477 was subsequently transferred to GSK in 2020. Progressing through a collaborative development venture, this compound has shown encouraging results in terms of mechanism, preclinical effectiveness, and safety profiles. These findings support its potential use in managing gut barrier integrity and diminishing gastrointestinal discomfort in conditions like ulcerative colitis and irritable bowel syndrome.

In mid-2023, regulatory clearance from the UK Medicines and Healthcare products Regulatory Agency was granted for the exploration of HTL0027477 in preliminary human trials.

Late in 2023, steps were taken to recapture the rights to this venture after GSK's decision to scale back on its advancement due to a revised outlook on immunology research and a shift in its research leadership. This decision did not stem from any concerns regarding the scientific, preclinical, or safety data pertaining to the drug candidate.

Subsequent to GSK's strategic move, Sosei Heptares reclaimed complete control over the HTL0027477 initiative, including all related intellectual property previously granted to GSK, and all preclinical findings produced from their alliance, all without an initial fee. Moving forward, Sosei Heptares aims to map out the most effective route for the future clinical progression of this program, which may involve direct development or seeking new partnership arrangements.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of March 25 2024, there are 7 investigational drugs for the GPR35 target, including 12 indications, 8 R&D institutions involved, with related clinical trials reaching 6, and as many as 230 patents.

GSK-4381406 targets GPR35 and focusing on digestive system disorders, particularly inflammatory bowel diseases. While the drug is currently in the preclinical phase, its potential to address the chronic inflammation associated with these conditions makes it an interesting candidate for further research and development.

图形用户界面, 文本, 应用程序

描述已自动生成

Master Loperamide Search on Synapse
Drug Insights
2 min read
Master Loperamide Search on Synapse
26 March 2024
Loperamide, an FDA-approved small molecule drug since December 1976, is a puzzling substance that binds to opioid receptors.
Read →
Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
Hot Spotlight
10 min read
Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
26 March 2024
On March 20th, Idorsia, a Swiss pharma, announced FDA approval for their drug TRYVIO™ (aprocitentan) to be used alongside other antihypertensives for treating uncontrolled hypertension in adults.
Read →
Promising Early Results for ACELYRIN's Lonigutamab in Thyroid Eye Disease Studies
Latest Hotspot
3 min read
Promising Early Results for ACELYRIN's Lonigutamab in Thyroid Eye Disease Studies
26 March 2024
ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.
Read →
Entera Bio Reveals Promising Oral GLP-2 Pill Efficacy for Short Gut Syndrome
Latest Hotspot
3 min read
Entera Bio Reveals Promising Oral GLP-2 Pill Efficacy for Short Gut Syndrome
24 March 2024
Entera Bio Unveils Strong Drug Absorption Results for Innovative Oral GLP-2 Hormone Pill Designed for Individuals with Short Gut Condition.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.